MX2022005044A - Formulacion de anticuerpo que contiene crizanlizumab. - Google Patents

Formulacion de anticuerpo que contiene crizanlizumab.

Info

Publication number
MX2022005044A
MX2022005044A MX2022005044A MX2022005044A MX2022005044A MX 2022005044 A MX2022005044 A MX 2022005044A MX 2022005044 A MX2022005044 A MX 2022005044A MX 2022005044 A MX2022005044 A MX 2022005044A MX 2022005044 A MX2022005044 A MX 2022005044A
Authority
MX
Mexico
Prior art keywords
crizanlizumab
containing antibody
antibody formulation
antibody
formulations
Prior art date
Application number
MX2022005044A
Other languages
English (en)
Inventor
Juergen Sigg
Fabian Bickel
Lina Boado
Dirk Chelius
Francois Griaud
Caroline Hilbert
Frieder Kroener
Rajsekhar Paul
Maja Anko
Aljosa Jelenko
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022005044A publication Critical patent/MX2022005044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas formulaciones farmacéuticas de un anticuerpo contra P-selectina humana, en especial SEG101, o un anticuerpo que tiene como máximo 3 aminoácidos de diferencia respecto de crizanlizumab, procesos para su preparación y usos de las formulaciones.
MX2022005044A 2019-10-30 2020-10-29 Formulacion de anticuerpo que contiene crizanlizumab. MX2022005044A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15
PCT/US2020/057868 WO2021087050A1 (en) 2019-10-30 2020-10-29 Crizanlizumab containing antibody formulation

Publications (1)

Publication Number Publication Date
MX2022005044A true MX2022005044A (es) 2022-05-16

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005044A MX2022005044A (es) 2019-10-30 2020-10-29 Formulacion de anticuerpo que contiene crizanlizumab.

Country Status (16)

Country Link
US (1) US20220378912A1 (es)
EP (1) EP4051236A1 (es)
JP (1) JP2023501155A (es)
KR (1) KR20220092917A (es)
CN (1) CN114828826A (es)
BR (1) BR112022008097A2 (es)
CA (1) CA3158921A1 (es)
CL (1) CL2022001085A1 (es)
CO (1) CO2022005207A2 (es)
EC (1) ECSP22033601A (es)
IL (1) IL292403A (es)
JO (1) JOP20220097A1 (es)
MX (1) MX2022005044A (es)
PE (1) PE20221276A1 (es)
TW (1) TW202128221A (es)
WO (1) WO2021087050A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2662091T (lt) 2006-12-01 2018-12-10 Novartis Ag Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
JOP20190101A1 (ar) 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
EP3624846A1 (en) * 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3762424A1 (en) * 2018-03-08 2021-01-13 Novartis AG Use of an anti-p-selectin antibody

Also Published As

Publication number Publication date
ECSP22033601A (es) 2022-05-31
WO2021087050A1 (en) 2021-05-06
EP4051236A1 (en) 2022-09-07
US20220378912A1 (en) 2022-12-01
PE20221276A1 (es) 2022-09-05
BR112022008097A2 (pt) 2022-08-02
TW202128221A (zh) 2021-08-01
AU2020373017A1 (en) 2022-05-19
JOP20220097A1 (ar) 2023-01-30
CA3158921A1 (en) 2021-05-06
KR20220092917A (ko) 2022-07-04
JP2023501155A (ja) 2023-01-18
CO2022005207A2 (es) 2022-05-10
CL2022001085A1 (es) 2023-02-03
IL292403A (en) 2022-06-01
CN114828826A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2020097537A3 (en) Fused ring compounds
MX2021004431A (es) Procesos novedosos.
MX2019009358A (es) Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
WO2020198403A3 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
PH12020550341A1 (en) Niraparib formulations
WO2021021837A3 (en) Anti-pvrig antibodies formulations and uses thereof
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
WO2019215063A8 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2021005607A (es) Proteinas f de prefusion del vrs estabilizadas.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
MX2020008125A (es) Composiciones que comprenden berberina.
WO2018091729A3 (en) Aqueous pharmaceutical formulations
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA202192925A1 (ru) Твердые формы ингибитора glyt1
EP4252849A3 (en) Depot systems comprising glatiramer acetate
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2022000712A (es) Moduladores de nlrp3.
WO2018170236A9 (en) CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS
PH12020551618A1 (en) Erenumab compositions and uses thereof
JOP20220097A1 (ar) كريزانليزوماب يحتوي على صياغات اجسام مضادة
ZA202200331B (en) Naltrexone formulation